DOI: 10.1128/AAC.43.1.169
Article Figures & Data
Tables
- Table 1.
In vitro susceptibilities of 566 clinical isolates ofC. neoformans to voriconazole and itraconazole stratified by fluconazole susceptibility category
Fluconazole susceptibility category (μg/ml)a Isolate source No. of isolates tested MIC (μg/ml) Itraconazole Voriconazole Range MIC50 MIC90 Range MIC50 MIC90 ≤8.0 Africa 154 0.06–0.5 0.25 0.5 0.015–0.25 0.12 0.12 United States 321 ≤0.007–0.5 0.25 0.5 ≤0.007–0.12 0.06 0.06 All 475 ≤0.007–0.5 0.25 0.5 ≤0.007–0.25 0.06 0.12 16–32 Africa 10 0.25–1.0 0.5 1.0 0.25–0.5 0.25 0.25 United States 78 0.25–1.0 0.5 1.0 0.03–0.5 0.12 0.25 All 88 0.25–1.0 0.5 1.0 0.03–0.5 0.12 0.25 ≥64 Africa United States 3 0.5–1.0 0.5 0.25–2.0 1.0 All 3 0.5–1.0 0.5 0.25–2.0 1.0 Total Africa 164 0.06–1.0 0.25 0.5 0.015–0.5 0.12 0.25 United States 402 ≤0.007–1.0 0.25 0.5 ≤0.007–2.0 0.06 0.12 All 566 ≤0.007–1.0 0.25 0.5 ≤0.007–2.0 0.06 0.12 ↵a Fluconazole MICs ranged from 0.12 to >128 μg/ml with a MIC50 of 8.0 μg/ml (both United States and Africa) and a MIC90 of 16 μg/ml (United States, 16 μg/ml; Africa, 8.0 μg/ml).
